Therapeutic implications of B-RAF mutations in colorectal cancer

摘要: Colorectal cancers (CRC) with B-RAF mutation carry a particularly poor prognosis. In this context, the value of first-line intensified chemotherapy associated an anti-VEGF (Vascular endothelial growth factor) to treat metastatic CRC has recently been called into question. patients mutated B-RAF, efficacy anti-EGFR (Epidermal Growth Factor Receptor) for treatment is uncertain while that shown be effective. The therapeutic pathways involving inhibition activity, although ineffective as monotherapy, have received marketing authorization when used in association second-line CRC. Immunotherapy provided very encouraging results recent phase III study microsatellite instability, irrespective their status. Finally, new therapies, targeting other RAF proteins and specific receptors are currently under development. Surgery liver metastases should considered whenever possible, after complete search peritoneal carcinomatosis distant metastases, similarly workup without mutation.